Ionis Pharmaceuticals, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Ionis Pharmaceuticals, Inc. (IONS) reported Cash and Cash Equivalents, Period Increase (Decrease) of $149.19 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-03-01
- Ionis Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$201.07M.
- Ionis Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$325.60M, a 1343.08% decline year-over-year.
- Ionis Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $577.99M, a 2979.30% increase year-over-year.
- Ionis Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $97.88M, a 231.38% increase year-over-year.
- Ionis Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $149.19M, a 231.94% increase from fiscal 2017.
- Ionis Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $44.95M.
- Ionis Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$44.11M.
- Ionis Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$14.20M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$201.07M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$526.67M derived: sum of 2 quarters · filed 2019-03-01 | $51.31M derived: sum of 3 quarters · filed 2019-03-01 | $149.19M 10-K · filed 2019-03-01 |
| 2018-09-30 | -$325.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $252.39M derived: sum of 2 quarters · filed 2018-11-06 | $350.26M 10-Q · filed 2018-11-06 | $320.71M derived: sum of 4 quarters · filed 2019-03-01 |
| 2018-06-30 | $577.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $675.86M 10-Q · filed 2018-08-07 | $646.31M derived: sum of 3 quarters · filed 2019-03-01 | $672.50M derived: sum of 4 quarters · filed 2019-03-01 |
| 2018-03-31 | $97.88M 10-Q · filed 2018-05-07 | $68.32M derived: sum of 2 quarters · filed 2019-03-01 | $94.51M derived: sum of 3 quarters · filed 2019-03-01 | $113.28M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-12-31 | -$29.55M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$3.36M derived: sum of 2 quarters · filed 2019-03-01 | $15.41M derived: sum of 3 quarters · filed 2019-03-01 | $44.95M 10-K · filed 2019-03-01 |
| 2017-09-30 | $26.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $44.96M derived: sum of 2 quarters · filed 2018-11-06 | $74.50M 10-Q · filed 2018-11-06 | $74.91M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $18.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $48.31M 10-Q · filed 2018-08-07 | $48.72M derived: sum of 3 quarters · filed 2019-03-01 | $20.46M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $29.54M 10-Q · filed 2018-05-07 | $29.95M derived: sum of 2 quarters · filed 2019-03-01 | $1.69M derived: sum of 3 quarters · filed 2019-03-01 | |
| 2016-12-31 | $410.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$27.85M derived: sum of 2 quarters · filed 2019-03-01 | -$44.11M 10-K · filed 2019-03-01 | |
| 2016-09-30 | -$28.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$44.52M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | -$16.26M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | -$14.20M 10-K · filed 2018-02-28 | |||
| 2012-09-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $28.17M derived: sum of 2 quarters · filed 2012-11-06 | $19.09M 10-Q · filed 2012-11-06 | $29.30M derived: sum of 4 quarters · filed 2012-11-06 |
| 2012-06-30 | $29.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-06 | $20.17M 10-Q · filed 2012-08-06 | $30.38M derived: sum of 3 quarters · filed 2012-08-06 | $623.00K derived: sum of 4 quarters · filed 2012-11-06 |
| 2012-03-31 | -$9.09M 10-Q · filed 2012-05-09 | $1.13M derived: sum of 2 quarters · filed 2012-05-09 | -$28.63M derived: sum of 3 quarters · filed 2012-11-06 | -$29.81M derived: sum of 4 quarters · filed 2012-11-06 |
| 2011-12-31 | $10.21M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$19.55M derived: sum of 2 quarters · filed 2012-11-06 | -$20.72M derived: sum of 3 quarters · filed 2012-11-06 | -$4.58M 10-K · filed 2012-02-29 |
| 2011-09-30 | -$29.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | -$30.94M derived: sum of 2 quarters · filed 2012-11-06 | -$14.79M 10-Q · filed 2012-11-06 | -$44.86M derived: sum of 4 quarters · filed 2012-11-06 |
| 2011-06-30 | -$1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-06 | $14.97M 10-Q · filed 2012-08-06 | -$15.10M derived: sum of 3 quarters · filed 2012-08-06 | $38.98M derived: sum of 4 quarters · filed 2012-08-06 |
| 2011-03-31 | $16.15M 10-Q · filed 2012-05-09 | -$13.92M derived: sum of 2 quarters · filed 2012-05-09 | $40.16M derived: sum of 3 quarters · filed 2012-05-09 | -$12.39M derived: sum of 4 quarters · filed 2012-05-09 |
| 2010-12-31 | -$30.07M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $24.01M derived: sum of 2 quarters · filed 2012-02-29 | -$28.54M derived: sum of 3 quarters · filed 2012-02-29 | -$35.20M 10-K · filed 2012-02-29 |
| 2010-09-30 | $54.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $1.53M derived: sum of 2 quarters · filed 2011-11-08 | -$5.13M 10-Q · filed 2011-11-08 | -$49.17M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | -$52.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-08 | -$59.22M 10-Q · filed 2011-08-08 | -$103.25M derived: sum of 3 quarters · filed 2012-02-29 | -$169.75M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | -$6.67M 10-Q · filed 2011-05-06 | -$50.70M derived: sum of 2 quarters · filed 2012-02-29 | -$117.20M derived: sum of 3 quarters · filed 2012-02-29 | |
| 2009-12-31 | -$44.04M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$110.53M derived: sum of 2 quarters · filed 2012-02-29 | -$118.73M 10-K · filed 2012-02-29 | |
| 2009-09-30 | -$66.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-05 | -$74.69M 10-Q · filed 2010-11-05 | ||
| 2009-06-30 | -$8.20M 10-Q · filed 2010-08-09 | |||
| 2008-12-31 | $85.37M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |